Related Experiment Video
Updated: Sep 27, 2025
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.6K
Alzheimer's: The ABCDE Paradigm.
Mayuri Gupta1, Donald F Weaver1,2
1Krembil Research Institute, University Health Network, 60 Leonard Avenue, Toronto M5T 0S8, Canada.
ACS Chemical Neuroscience
|April 15, 2022
Summary
Developing new Alzheimer's disease (AD) therapies requires a paradigm shift. The ABCDE framework guides the creation of accessible, blood-brain barrier-permeant, cognitive-enhancing, disease-modifying, and non-toxic treatments for AD.
Area of Science:
- Neuropharmacology
- Drug Development
- Dementia Research
Background:
- Alzheimer's disease (AD) and related dementias represent a significant global health challenge.
- Numerous investigational agents for AD have failed over the past two decades, necessitating novel therapeutic strategies.
- There is an urgent need for effective treatments to address the growing dementia crisis.
Purpose of the Study:
- To introduce the ABCDE paradigm as a conceptual framework for developing Alzheimer's disease therapeutics.
- To outline key criteria for designing safe and effective treatments for Alzheimer's disease.
- To guide future neuropharmacologic research and drug development for AD.
Main Methods:
- Conceptual framework development.
- Literature review of past AD therapeutic failures and successes.
- Defining essential characteristics for successful AD drug candidates.
Main Results:
- The ABCDE paradigm provides a structured approach to drug development for AD.
- Key criteria include: Accessible, Blood-brain barrier permeant, Cognitive enhancing, Disease-modifying, and Environmentally non-toxic.
- This framework aims to improve the success rate of therapeutic agents for AD.
Conclusions:
- The ABCDE paradigm offers a novel conceptual tool to advance the development of Alzheimer's disease cures.
- Adherence to these criteria can potentially overcome previous hurdles in AD drug development.
- This approach prioritizes the creation of safe, effective, and globally viable solutions for Alzheimer's disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
696
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
696
01:22Alzheimer's Disease: Treatment
272
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
272
01:30Dementia
191
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
191
01:15Parkinson's Disease: Overview
758
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
758
01:13Amnesia
206
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
206
01:30Cognitive Development During Adulthood
337
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
337